Lee Gary K. sold $2K of LYEL
Lee Gary K. (Chief Scientific Officer) sold 131 shares of Lyell Immunopharma, Inc. (LYEL) at $14.34 on 2026-08-10.
How this was made
The 30-second read
Why it matters
This provides incremental transparency on insider activity but does not include any new clinical, regulatory, financial, or deal catalyst for Lyell.
Market read
Traders may note insider selling, but the transaction size and lack of additional company news suggest limited trading impact.
What to watch
Insider sales can be driven by diversification, taxes, or pre-existing personal liquidity needs; the filing lacks context on motivations or broader insider activity.
Background
The article is a SEC Form 4 insider transaction disclosure for Lyell Immunopharma, Inc.
Ticker impact
Lyell Immunopharma disclosed an insider Form 4 sale by CSO Lee Gary K., selling 131 shares at $14.34 on 2026-08-10.
Low likelihood of a sustained price move solely from this transaction.
The filing is a Form 4 open-market sale with modest proceeds ($1,878.54) and no 10b5-1 plan stated, but insider sales are often non-informational and the article provides no new company-specific operating or regulatory catalyst.
Market effects
No clear sector read-through from a small, routine insider sale.
None indicated.
None indicated.
Counterpoint
Absence of a stated 10b5-1 plan could be interpreted as less mechanical selling, but the small size makes it unlikely to be a strong fundamental signal.
Key entities
- issuerLyell Immunopharma, Inc.
Subject of the Form 4 insider transaction disclosure (LYEL).
- insiderLee Gary K.
Chief Scientific Officer who sold 131 shares in an open-market transaction.